Literature DB >> 35015195

Novel combined fibrosis-based index predicts the long-term outcomes of hepatocellular carcinoma after hepatic resection.

Mitsuru Yanagaki1, Yoshihiro Shirai2, Ryoga Hamura1, Tomohiko Taniai1, Yoshiaki Tanji1, Koichiro Haruki1, Kenei Furukawa1, Shinji Onda1, Hiroaki Shiba1, Toru Ikegami1.   

Abstract

AIM: Liver fibrosis influences liver regeneration and surgical outcomes. The fibrosis-4 (FIB-4) index is strongly associated with liver fibrosis and cirrhosis. This study aimed to examine the prognostic significance of the combination of FIB-4 index and Protein Induced by Vitamin K Absence or Antagonist-II (PIVKA-II) (PIVKA-II-FIB-4 index score) in patients who underwent curative resection for hepatocellular carcinoma (HCC).
METHODS: We included 284 patients who underwent elective hepatic resection for HCC between January 2000 and December 2018. We retrospectively investigated how FIB-4 index is related to disease-free survival and overall survival.
RESULTS: According to a receiver operating characteristic (ROC) analysis, the optimal cutoff value of the FIB-4 index was 3.44. In a multivariate analysis, high PIVKA-II and FIB-4 index values were independent predictors of both disease-free survival (P = 0.013 and P = 0.005, respectively) and overall survival (P = 0.048 and P < 0.001, respectively). We classified the PIVKA-II and FIB-4 index levels into two groups (high vs. low) and calculated a new score (PIVKA-II-FIB-4 index score; 0-2) by the sum of each measurement (high, 1; low, 0). The 5 year overall survival rates of patients with PIVKA-II-FIB-4 index scores of 0, 1, and 2 were 84.9, 74.4, and 47.1%, respectively (P < 0.001).
CONCLUSION: The combination of the preoperative PIVKA-II and FIB-4 index may be a prognostic factor of HCC after hepatic resection, suggesting that the combined score is useful in assessing the liver fibrosis status in cancer cases.
© 2022. The Author(s) under exclusive licence to Japan Society of Clinical Oncology.

Entities:  

Keywords:  Fibrosis-4 index; Hepatic resection; Hepatocellular carcinoma; PIVKA-II; Prognostic factor

Mesh:

Substances:

Year:  2022        PMID: 35015195     DOI: 10.1007/s10147-021-02111-7

Source DB:  PubMed          Journal:  Int J Clin Oncol        ISSN: 1341-9625            Impact factor:   3.402


  3 in total

1.  The diagnostic performance of PIVKA-II in metabolic and viral hepatocellular carcinoma: a pilot study.

Authors:  U Basile; L Miele; C Napodano; G Ciasca; F Gulli; K Pocino; N De Matthaeis; A Liguori; A De Magistris; G Marrone; M Biolato; M Marino; F Di Giacinto; A Gasbarrini; A Grieco; G L Rapaccini
Journal:  Eur Rev Med Pharmacol Sci       Date:  2020-12       Impact factor: 3.507

2.  A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma.

Authors:  G Bertino; A M Ardiri; P M Boemi; D Ierna; D Interlandi; L Caruso; E Minona; M A Trovato; S Vicari; G Li Destri; S Puleo
Journal:  Panminerva Med       Date:  2008-09       Impact factor: 5.197

3.  Fibrosis-4 Model Influences Results of Patients with Hepatocellular Carcinoma Undergoing Hepatectomy.

Authors:  Haiqing Wang; Aixiang Liu; Wentao Bo; Xielin Feng; Yong Hu; Lang Tian; Hui Zhang; Xiaoli Tang; Lixia Zhang
Journal:  Biomed Res Int       Date:  2018-07-02       Impact factor: 3.411

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.